secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001140361-22-041169
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant reports Q2 net loss $316M; VTAMA net revenue $5M; cash runway extended to H2 2025
--------------------------------------------------------------------------------

- Net loss $315.9M ($0.42/share); non-GAAP net loss $226.8M improved from $290.0M YoY.
- VTAMA net product revenue $5.0M; over 54,000 prescriptions by ~6,400 prescribers since launch.
- Cash, equivalents and restricted cash $1.6B; runway extended to H2 2025 after offerings and Myovant proceeds.
- Completed enrollment for brepocitinib SLE potentially registrational trial; data H2 2023.
- Federal court denied Moderna's motion to dismiss Genevant/Arbutus IP suit; discovery proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036122041169/0001140361-22-041169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036122041169/brhc10044087_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-041169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer